Proteinuria Higher With Dasatinib Exposure in Chronic Myelogenous Leukemia

WEDNESDAY, Sept. 20, 2023 -- For patients with chronic myelogenous leukemia (CML) receiving tyrosine-kinase inhibitor therapy, exposure to dasatinib is associated with increased odds of proteinuria, according to a study published online in the...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news